X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Therapeutics and Clinical Risk Management

期刊標題檢索 THER CLIN RISK 最新評論: What's going on with me (2022-09-12)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Therapeutics and Clinical Risk Management]您好,您是該頁面的第 5962 位訪客。

期刊簡介
期刊名稱Therapeutics and Clinical Risk Management Therapeutics and Clinical Risk Management
LetPub Score
4.8
50 ratings
Rate

Reputation
5.9

Influence
3.6

Speed
7.0

期刊簡稱THER CLIN RISK MANAG
ISSN1176-6336
E-ISSN1178-203X
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.300.7520.963
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: General Pharmacology, Toxicology and Pharmaceutics
Q110 / 80
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Safety Research
Q121 / 109
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Chemical Health and Safety
Q25 / 16
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology (medical)
Q293 / 272

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.

The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.

As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.

The journal does not accept study protocols, animal-based or cell line-based studies.
官方網站https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
在線稿件提交https://www.dovepress.com/submit_step_1.php
開放訪問Yes
出版商Dove Medical Press
主題領域Pharmacology, Toxicology and Pharmaceutics
出版國/地區New Zealand
發行頻率
創刊年0
每年文章數90每年文章數趨勢
黃金OA百分比99.36%
OA Related Info
APC: Yes( USD3300; )
APC waiver:Check Notes
Other charges: No
Keywords: clinical therapeutics、clinical risk management
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
HEALTH CARE SCIENCES & SERVICESSCIEQ277/174
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1176-6336%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 16 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Therapeutics and Clinical Risk Management】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Acta Pharmaceutica Sinica BH-index: 28

    CiteScore: 22.40
    Antibiotics-BaselH-index: 0

    CiteScore: 7.30
    Pharmacology Research & PerspectivesH-index: 0

    CiteScore: 5.30
    Revista Brasileira de Farmacognosia-Brazilian Journal of PharmacognosyH-index: 37

    CiteScore: 2.60
    Infarma Pharmaceutical SciencesH-index: 0

    CiteScore: 0.10
    Mental Health ClinicianH-index: 0

    CiteScore: 1.90
    Pharmacological Research Modern Chinese MedicineH-index: 0

    CiteScore: 1.60
    學科內最受檢索的期刊 頁面查看次數
    Acta Pharmaceutica Sinica B202580
    Antibiotics-Basel33464
    Pharmacology Research & Perspectives17138
    Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy15828
    Infarma Pharmaceutical Sciences1581
    Pharmacological Research Modern Chinese Medicine1298
    Mental Health Clinician418
  •  

    Therapeutics and Clinical Risk Management Therapeutics and Clinical Risk Management
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [Therapeutics and Clinical Risk Management] 的評論撰寫評論
作者: 宗室香灵


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-12 08:00:28 評論於
What's going on with me
(0) 讚! | 宗室香灵

作者: Megan Swinburne


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-10 17:42:16 評論於
Recently, I can't seem to open the official website and submission links of the journal. What's going on?
(0) 讚! | Megan Swinburne

作者: 北海宏雨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-22 10:51:36 評論於
The final verification showed that it was indeed SCI, but there was an error on the part of the journal editor, and the submission to Web of Science was missed, causing Web of Science unable to retrieve it
(0) 讚! | 北海宏雨

作者: 北海宏雨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-21 17:32:02 評論於
Review Speed: 6.0 | Submission Acceptance Rate: 50.0
Experience Sharing: This journal is not indexed in SCI, so don't bother. After I published, my unit couldn't find it in the SCI database. It can't be recognized, nor can it be reimbursed. This is the first time I've encountered such a bizarre situation
(0) 讚! | 北海宏雨

作者: 法慧淇钧


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-09 22:47:30 評論於
How is this magazine? Do all authors need to confirm after submitting their contributions? What if someone misses the email?
(0) 讚! | 法慧淇钧

作者: 法慧淇钧


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-09 21:26:25 評論於
How is this magazine? Does each author need to confirm after submitting a contribution? What if someone misses the email?
(0) 讚! | 法慧淇钧

作者: 法慧淇钧


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-09 14:55:59 評論於
How is this magazine? Does every author need to confirm after submission? What if someone didn't see the email?
(0) 讚! | 法慧淇钧

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 21:13:52 評論於
The writing of the discussion section, in contrast to the introduction, follows a funnel-shaped structure that expands from small to large. Starting from the reasonableness of each research result, anomalies, and underlying principles, a thorough analysis is slowly conducted. After laying the groundwork, the main conclusions of the paper can be naturally introduced for discussion, followed by further analysis to highlight the importance/significance/generality/application value of the research
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 19:12:30 評論於
Research Purpose, Process and Findings:
The purpose of this research was to investigate the impact of social media on consumer purchasing behavior. The study was conducted through surveys and data analysis of online shopping habits. The results revealed that social media has a significant influence on consumer decisions, with a strong correlation between social media engagement and purchasing choices.

Discussion of Data Results:
The data results indicated that social media platforms such as Instagram and Facebook play a crucial role in shaping consumer preferences and influencing buying decisions. Previous studies by Smith et al. (2018) and Liu et al. (2019) have also shown similar findings, highlighting the importance of social media marketing strategies in the digital age.

Evaluation and Discussion of Research Contributions:
This research contributes to the existing literature by providing empirical evidence of the impact of social media on consumer behavior. The findings have implications for marketers and businesses aiming to leverage social media platforms for advertising and brand promotion. The study underscores the importance of understanding consumer trends in the digital era and adapting marketing strategies accordingly.

Future Research Directions:
In conclusion, this study highlights the significance of social media in influencing consumer purchasing behavior. Moving forward, future research should explore the effectiveness of different social media marketing tactics and further examine the relationship between social media engagement and consumer decision-making processes
(0) 讚! | 维尔娜菲茨杰拉德

作者: 修然小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 23:24:34 評論於
What is the difference between an introduction and a discussion?
(0) 讚! | 修然小公主

作者: Darlene Pepys


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 20:10:27 評論於
How should we write the discussion?
(0) 讚! | Darlene Pepys

作者: 佳怡baby


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-02-20 10:46:40 評論於
Can you recommend any magazines that you receive?
(0) 讚! | 佳怡baby

作者: Duncan Stilwell


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-11-09 16:21:45 評論於
Review Speed: 3.0 | Submission Acceptance Rate: 50.0
Sharing Experience: When it comes to feeling that the reviewers are not responsible, they just mention lack of innovation without providing any specific feedback. As a result, a submission that received over 2 points was accepted
(0) 讚! | Duncan Stilwell

作者: Colbert Cecillia


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-12-03 17:58:23 評論於
Quite expensive, it costs over $2000
(0) 讚! | Colbert Cecillia

作者: 是你的和洽呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-09-21 17:49:21 評論於
How much is the layout fee? CarrieXu 2019-06-21 00:00:00 Posted: Yes, the impact factor from Web of Science is 1.824, why wasn't it updated here promptly?
(0) 讚! | 是你的和洽呀

作者: 北风山岭


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-07-04 22:18:34 評論於
Just accept the case
(0) 讚! | 北风山岭

作者: 辉夜华采


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-21 19:03:33 評論於
Yes, the web of science shows 1.824 points, why is it not updated here in time?
(0) 讚! | 辉夜华采

作者: 是曼丽吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-21 09:54:04 評論於
Wrong. I checked and it's actually 1.824, not 0 points
(0) 讚! | 是曼丽吖

作者: 佛光初玉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-01-21 10:21:43 評論於
Will you accept the modified version?
(0) 讚! | 佛光初玉

作者: 晨风静恬


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-10-19 12:51:18 評論於
What does "3B accept with changes" mean? 
Cardiac_08_49511499 2018-09-09 Posted: Acceptance rate: about 75% Review time: about 1 month Dove magazine is now too slow. I have submitted two articles before, and it used to be quite fast. Now maybe they have more manuscripts, just look at the speed at which they publish
(0) 讚! | 晨风静恬

作者: Eudora Boswell


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-09-08 08:54:02 評論於
Review speed: 1.0 | Submission hit rate: 75.0 Experience sharing: Dove magazine is too slow now. I have had two submissions accepted before, and it used to be quite fast. But now, maybe they have more submissions to deal with, you can tell from their publication speed
(0) 讚! | Eudora Boswell

作者: 岭南莹雪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-07-21 23:00:57 評論於
How long has it been
spj108 posted on 2018-07-20 00:00:00: My status has been stuck at 2A - PEER REVIEW INVITATIONS SENT for so long. Can someone please advise on the situation?
(0) 讚! | 岭南莹雪

作者: 彤霞少女


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-07-19 08:57:50 評論於
My status has been stuck at 2A - PEER REVIEW INVITATIONS SENT and hasn't changed. Could you please advise?
(0) 讚! | 彤霞少女

作者: 岭南莹雪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-04-04 23:32:29 評論於
Review speed: 3.0 | Submission acceptance rate: 50.0
Experience sharing: Encountering a good editor is the most important
(0) 讚! | 岭南莹雪

作者: 七星怡木


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-06-22 23:54:30 評論於
How to register? Fill in according to the instructions, and also need to prove that you are not a robot, how to prove it, please help
(0) 讚! | 七星怡木

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [Therapeutics and Clinical Risk Management] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*